Enabling CAR T‐cell therapies for HIV‐positive lymphoma patients – A call for action

People living with HIV have a higher risk of developing lymphoma. Outcomes for people living with HIV with relapsed or refractory (r/r) lymphoma remain poor. For this group of patients, chimeric antigen receptor (CAR) T‐cell therapy represents a new successful treatment strategy. However, people liv...

Full description

Saved in:
Bibliographic Details
Published in:HIV medicine 2023-09, Vol.24 (9), p.957-964
Main Authors: Hattenhauer, Tessa, Mispelbaum, Rebekka, Hentrich, Marcus, Boesecke, Christoph, Monin, Malte Benedikt
Format: Article
Language:English
Subjects:
Antigens
CAR T‐cell therapy
CAR T‐cells
Case reports
CD4 antigen
Cell therapy
Chimeric antigen receptors
Clinical trials
DLBCL
Health services
HIV
Human immunodeficiency virus
Lymphoma
Neurotoxicity
Patients
Remission
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:People living with HIV have a higher risk of developing lymphoma. Outcomes for people living with HIV with relapsed or refractory (r/r) lymphoma remain poor. For this group of patients, chimeric antigen receptor (CAR) T‐cell therapy represents a new successful treatment strategy. However, people living with HIV were not included in pivotal trials, so data are limited to case reports. We searched the PubMed and Ovid technologies databases for literature until 1 November 2022 using the terms ‘HIV and CAR‐T’, ‘HIV and lymphoma’ and ‘HIV and CAR‐T and lymphoma’. Six cases with sufficient information were included in the review. The mean CD4+ T‐cell count before CAR T‐cell therapy was 221 cells/μL (range 52–629). The viral load was below the limit of detection in four patients. All patients had diffuse large B‐cell lymphoma (DLBCL) and were treated with gamma‐retroviral‐based axicabtagene ciloleucel. Four patients developed cytokine‐release syndrome (CRS) grade 2 or less or immune effector‐cell‐associated neurotoxicity syndrome (ICANs) grade 3–4. Four of six patients responded to CAR T‐cell therapy (three complete remissions, one partial remission). In summary, there are no clinical reasons to restrict the use of CAR T‐cell therapy in people living with HIV with r/r DLBCL. According to the current data, CAR T‐cell therapy was safe and effective. In people who meet the standard criteria for CAR T‐cell therapy, this treatment approach could significantly improve the unmet need for more effective treatment options for people living with HIV with r/r lymphoma.
ISSN:1464-2662
1468-1293
DOI:10.1111/hiv.13514